CompletedPhase 2

Onsite Buprenorphine Treatment at Syringe Exchange Programs

United States97 participantsStarted 2019-01-02

Plain-language summary

This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age ≥ 18 years
✓. opioid use disorder
✓. interest in buprenorphine treatment
✓. motivation for opioid use disorder treatment
✓. willingness to accept community health center referral
✓. syringe exchange participant

Exclusion criteria

✕. receiving opioid agonist treatment in the past 30 days (confirmed by New York Prescription Drug Monitoring Program);
✕. inability to provide informed consent
✕. unstable mental illness (e.g., suicidality, psychosis, etc.)
✕. severe alcohol use disorder or benzodiazepine use disorder by the Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria
✕. hypersensitivity to buprenorphine or naloxone.
✕. pregnancy (confirmed via urine testing)

What they're measuring

Buprenorphine Engagement

Timeframe: 30 days after randomization

Trial details

NCT IDNCT03150173

SponsorMontefiore Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-11

Results submitted2024-12-18

View on ClinicalTrials.gov More Opiate Addiction trials